ATE231142T1 - Cyclopropachromencarbonsäure derivate - Google Patents

Cyclopropachromencarbonsäure derivate

Info

Publication number
ATE231142T1
ATE231142T1 AT95934860T AT95934860T ATE231142T1 AT E231142 T1 ATE231142 T1 AT E231142T1 AT 95934860 T AT95934860 T AT 95934860T AT 95934860 T AT95934860 T AT 95934860T AT E231142 T1 ATE231142 T1 AT E231142T1
Authority
AT
Austria
Prior art keywords
group
carbon atoms
substituted
hydrogen atom
atom
Prior art date
Application number
AT95934860T
Other languages
English (en)
Inventor
Hirokazu Annoura
Atsuko Fukunaga
Toshio Tatsuoka
Yoshiko Horikawa
Original Assignee
Suntory Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Ltd filed Critical Suntory Ltd
Application granted granted Critical
Publication of ATE231142T1 publication Critical patent/ATE231142T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
AT95934860T 1994-10-21 1995-10-20 Cyclopropachromencarbonsäure derivate ATE231142T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP25646894 1994-10-21
JP22536595A JP3993651B2 (ja) 1994-10-21 1995-09-01 シクロプロパクロメンカルボン酸誘導体
PCT/JP1995/002163 WO1996012715A1 (en) 1994-10-21 1995-10-20 Cyclopropachromenecarboxylate derivatives

Publications (1)

Publication Number Publication Date
ATE231142T1 true ATE231142T1 (de) 2003-02-15

Family

ID=26526593

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95934860T ATE231142T1 (de) 1994-10-21 1995-10-20 Cyclopropachromencarbonsäure derivate

Country Status (7)

Country Link
US (1) US5843988A (de)
EP (1) EP0787723B1 (de)
JP (1) JP3993651B2 (de)
AT (1) ATE231142T1 (de)
DE (1) DE69529418T2 (de)
ES (1) ES2191063T3 (de)
WO (1) WO1996012715A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19801636A1 (de) 1998-01-17 1999-07-22 Bayer Ag Substituierte bicyclische Lactone
DE19801646A1 (de) * 1998-01-17 1999-07-22 Bayer Ag Substituierte alpha,beta-annellierte Butyrolactone
DE19801647A1 (de) 1998-01-17 1999-07-22 Bayer Ag Substituierte beta,gamma-annellierte Lactone
WO1999044639A1 (en) * 1998-03-03 1999-09-10 Yamanouchi Pharmaceutical Co., Ltd. Remedies for brain infarction
GB9823845D0 (en) * 1998-11-02 1998-12-23 Lilly Co Eli Pharmaceutical compounds
AU2241400A (en) 1999-04-06 2000-10-12 Yamanouchi Pharmaceutical Co., Ltd. Novel thiazolobenzoimidazole derivative
GB0007193D0 (en) * 2000-03-25 2000-05-17 Univ Manchester Treatment of movrmrnt disorders
US6660858B2 (en) * 2001-03-28 2003-12-09 Lion Bioscience Ag 2-aminobenzoxazole derivatives and combinatorial libraries thereof
US20060166972A1 (en) * 2003-07-11 2006-07-27 Conn P J Treatment of movement disorders with a metabotropic glutamate 4 receptor positive allosteric modulator
WO2006025070A2 (en) 2004-07-30 2006-03-09 Torrent Pharmaceuticals Limited Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol
DE102005011534A1 (de) * 2005-03-10 2006-09-21 Merck Patent Gmbh Chromen-4-on-Derivate
EP2258357A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese mit Acetylcholinesterasehemmer
EP2275096A3 (de) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenese durch modulation des Muscarinrezeptors
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP2314289A1 (de) 2005-10-31 2011-04-27 Braincells, Inc. Gaba-rezeptor-vermittelte modulation von neurogenese
DE102005062990A1 (de) * 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte Thiazole und ihre Verwendung zur Herstellung von Arzneimitteln
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
EP2021000A2 (de) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenese mittels angiotensin-modulation
WO2008030651A1 (en) * 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2011051478A1 (en) 2009-10-30 2011-05-05 Domain Therapeutics Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors
AU2015308438B2 (en) 2014-08-27 2018-12-13 Prexton Therapeutics Sa Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors
KR20180041234A (ko) 2015-08-27 2018-04-23 프렉스톤 테라퓨틱스 에스에이 레보도파로 유발된 이상운동증 치료용 뇌 침투성 크로몬 옥심 유도체

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0723367B2 (ja) * 1986-02-27 1995-03-15 サントリー株式会社 オキサビシクロヘプタン誘導体
CA2037188A1 (en) * 1990-06-06 1991-12-07 Toshio Tatsuoka Agent for treating disorders from cerebral neuro-degeneration
CA2037187A1 (en) * 1990-06-06 1991-12-07 Toshio Tatsuoka Cyclopropachromen derivatives
DE4018468A1 (de) * 1990-06-08 1991-12-12 Ultrakust Electronic Gmbh Verfahren und vorrichtung zur entnahme einer repraesentativen milchprobe

Also Published As

Publication number Publication date
WO1996012715A1 (en) 1996-05-02
DE69529418T2 (de) 2003-08-14
DE69529418D1 (de) 2003-02-20
EP0787723A4 (de) 1998-02-04
ES2191063T3 (es) 2003-09-01
JPH08169884A (ja) 1996-07-02
JP3993651B2 (ja) 2007-10-17
US5843988A (en) 1998-12-01
EP0787723A1 (de) 1997-08-06
EP0787723B1 (de) 2003-01-15

Similar Documents

Publication Publication Date Title
DE69529418D1 (de) Cyclopropachromencarbonsäure derivate
DE69206820D1 (de) 1,3-Dihydro-2H-Imidano 4,5-b-quinolin-2-ein Derivate als Phosphodiestenase Hemmer
MY131297A (en) Herbicides
DK0870768T3 (da) Azaindol-ethylaminderivater som nikotinacetylcholinreceptor-bindingsmidler
DK0590919T3 (da) Terapeutiske midler mod Parkinsons sygdom
NZ509045A (en) Intermediates in the formation of antivirally active heterocyclic azahexane derivatives
FI942635A0 (fi) Piperatsiinijohdannaiset 5HT1A-antagonisteina
DK0572093T3 (da) Herbicide 2,6-substituerede pyridiner
DK0381422T3 (da) Tetrahydrobenzimidazolderivater
EP1110961A4 (de) Sauerstoffhaltige heterocyclische verbindungen
EP1004573A4 (de) Aryloxyanilin-derivate
MX9101232A (es) Derivados de benceno,piridina y pirimidina
DE69733308D1 (de) Aktivsauerstoffaufnehmer enthaltende pterinderivate
DE69122427D1 (de) Imidazonaphthyridinderivate
DE60016384D1 (de) Chondrogonese promotoren und indolin-2-on derivate
DE69512816D1 (de) Oxopyridylchinoxalin Derivate
DK0806413T3 (da) 2-substituerede viatmin D3-derivater
ATE504572T1 (de) Derivate von aromatische heterocyclen enthaltende integraseinhibitoren
NO20023041D0 (no) Fremgangsmåte for fremstilling av pyrazolopyridazinderivater
EP0719773A4 (de) Imidazolidinon-derivate, deren säure-additionssalze und her mittel gegen senile demenz
ATE151750T1 (de) 3-(indol-3-yl) propensäurderivate, die als nmda- antagonisten nützlich sind
MX9202178A (es) Nuevos derivados de 2-piperacinil bencimidazol.
ATE105565T1 (de) Pradimicinderivate.
ES2141134T3 (es) Derivados de carbamoil pirrolidona para el tratamiento de la depresion y de los trastornos cerebrovasculares.
DE69116302D1 (de) 4-[4- oder 6-(Trifluormethyl-2-pyridinyl)]-1-piperazinyl-alkyl substituierte Laktame

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties